Additional file 7: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

Publication date

August 2018

DOI

10.6084/m9.figshare.6973481.v1

Abstract

Mean change from baseline in HAQ-DI by visit (ITT population). Abbreviations: Adalimumab-EU adalimumab sourced from the European Union, HAQ-DI health assessment questionnaire disability index, ITT intention-to-treat (PNG 84 kb

Extracted data

We use cookies to provide a better user experience.

Data Protection

Additional file 7: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

Open link

Publication date

August 2018

DOI

10.6084/m9.figshare.6973481.v1

Abstract

Extracted data

Vibeke Strand (410780)
Joel Kremer (3475457)
Gene Wallenstein (3475451)
Keith Kanik (3475454)
Carol Connell (3475442)
David Gruben (3475448)
Samuel Zwillich (3475445)
Roy Fleischmann (96247)

November 2015

Numbers needed to treat for ACR 20/50/70 (a), Disease Activity Score based on C reactive protein and...

Additional file 5: Table S4. of Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs

Vibeke Strand (410780)
Joel Kremer (3475457)
Gene Wallenstein (3475451)
Keith Kanik (3475454)
Carol Connell (3475442)
David Gruben (3475448)
Samuel Zwillich (3475445)
Roy Fleischmann (96247)

November 2015

Rates of reporting normative values for the Health Assessment Questionnaire-Disability Index (HAQ-DI...

Additional file 3: of Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study

Motomu Hashimoto (388292)
Moritoshi Furu (105348)
Wararu Yamamoto (5594390)
Takanori Fujimura (4966762)
Ryota Hara (4966744)
Masaki Katayama (152645)
Akira Ohnishi (4966750)
Kengo Akashi (3486011)
Shuzo Yoshida (525805)
Koji Nagai (4966753)
Yonsu Son (4966759)
Hideki Amuro (4966747)
Toru Hirano (2738686)
Kosuke Ebina (326525)
Ryuji Uozumi (5594393)
Hiromu Ito (164599)
Masao Tanaka (107633)
Koichiro Ohmura (137137)
Takao Fujii (199007)
Tsuneyo Mimori (114039)

August 2018

Table S1. Types of bDMARDs and hazard ratios for bDMARD-free remission failure in bDMARD-naïve patie...

Additional file 5: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

August 2018

EULAR response by study visit (ITT population). Abbreviations: EULAR European League Against Rheumat...

Additional file 3: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

August 2018

Consolidated Standards of Reporting Trials (CONSORT) flow diagram of patient progress in the two tre...

Additional file 6: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

August 2018

DAS28–4(CRP) of less than 2.6 and ACR/EULAR remission by study visit (ITT population). Abbreviations...

Additional file 8: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

August 2018

All-causality treatment-emergent adverse events in at least 2% of patients in any treatment arm (saf...

Additional file 9: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

August 2018

ADA and NAb incidence by study visit (safety population). Abbreviations: ADA anti-drug antibody, NAb...

Additional file 4: Figure S3. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

Mean change from baseline in ACR component parameters over time in the total population. (PDF 72 kb

Additional file 1: of Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis

Vibeke Strand (410780)
Laure Gossec (4058521)
Clare Proudfoot (5165081)
Chieh-I Chen (4415830)
Matthew Reaney (5424773)
Sophie Guillonneau (5424776)
Toshio Kimura (5424779)
Janet van Adelsberg (5424782)
Yong Lin (177139)
Erin Mangan (5424785)
Hubert van Hoogstraten (5079860)
Gerd Burmester (52016)

June 2018

Table S1. LSM changes in RAID individual domain scores from baseline to week 24 with sarilumab 200Â ...

Additional file 5: Figure S4. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

Mean DAS parameters and DAS responder rates over time in the total population. (PDF 111 kb

Additional file 1: of A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy

Stanley Cohen (411535)
Rieke Alten (52012)
Hideto Kameda (3399878)
Tomas Hala (5567096)
Sebastiao Radominski (5567099)
Muhammad Rehman (5567102)
Ramesh Palaparthy (4951276)
Karl Schumacher (5567105)
Susanne Schmitt (5567108)
Steven Hua (5567111)
Claudia Ianos (5567114)
K. Sewell (5614937)

July 2018

Supplementary methods and results, supplementary figures and figure legends, and supplementary table...

Additional file 1: of Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

Rieke Alten (52012)
Harald Burkhardt (23413)
Eugen Feist (609857)
Klaus KrĂźger (4763949)
Juergen Rech (4763922)
Andrea Rubbert-Roth (358862)
Reinhard Voll (23411)
Yedid Elbez (4763928)
Christiane Rauch (4763931)

January 2018

is a figure showing mean change from baseline in HAQ-DI scores in response to abatacept administered...

Additional file 3: Figure S2. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

ACR20 response rate and mean DAS28â4(ESR) and HAQ-DI over time for patients treated with tofacitin...

Additional file 1: of Health outcomes and unmet needs in patients with long-standing rheumatoid arthritis attending tertiary care in Greece: a cohort study

Dimitrios Boumpas (5800499)
Prodromos Sidiropoulos (424541)
Loukas Settas (6648626)
Piotr Szczypa (578620)
Vassilis Tsekouras (6648629)
Ana Hernandez Daly (6648632)

April 2019

Table S1. Final fitted mixed-effects model across study time points for EQ-5D index score. Table S2....

Vibeke Strand (410780)
Joel Kremer (3475457)
Gene Wallenstein (3475451)
Keith Kanik (3475454)
Carol Connell (3475442)
David Gruben (3475448)
Samuel Zwillich (3475445)
Roy Fleischmann (96247)

November 2015

Numbers needed to treat for ACR 20/50/70 (a), Disease Activity Score based on C reactive protein and...

Vibeke Strand (410780)
Joel Kremer (3475457)
Gene Wallenstein (3475451)
Keith Kanik (3475454)
Carol Connell (3475442)
David Gruben (3475448)
Samuel Zwillich (3475445)
Roy Fleischmann (96247)

November 2015

Rates of reporting normative values for the Health Assessment Questionnaire-Disability Index (HAQ-DI...

Additional file 3: of Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study

Motomu Hashimoto (388292)
Moritoshi Furu (105348)
Wararu Yamamoto (5594390)
Takanori Fujimura (4966762)
Ryota Hara (4966744)
Masaki Katayama (152645)
Akira Ohnishi (4966750)
Kengo Akashi (3486011)
Shuzo Yoshida (525805)
Koji Nagai (4966753)
Yonsu Son (4966759)
Hideki Amuro (4966747)
Toru Hirano (2738686)
Kosuke Ebina (326525)
Ryuji Uozumi (5594393)
Hiromu Ito (164599)
Masao Tanaka (107633)
Koichiro Ohmura (137137)
Takao Fujii (199007)
Tsuneyo Mimori (114039)

August 2018

Table S1. Types of bDMARDs and hazard ratios for bDMARD-free remission failure in bDMARD-naïve patie...

Additional file 5: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

August 2018

EULAR response by study visit (ITT population). Abbreviations: EULAR European League Against Rheumat...

Additional file 3: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

August 2018

Consolidated Standards of Reporting Trials (CONSORT) flow diagram of patient progress in the two tre...

Additional file 6: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

August 2018

DAS28–4(CRP) of less than 2.6 and ACR/EULAR remission by study visit (ITT population). Abbreviations...

Additional file 8: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

August 2018

All-causality treatment-emergent adverse events in at least 2% of patients in any treatment arm (saf...

Additional file 9: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

August 2018

ADA and NAb incidence by study visit (safety population). Abbreviations: ADA anti-drug antibody, NAb...

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

Mean change from baseline in ACR component parameters over time in the total population. (PDF 72 kb

Additional file 1: of Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis

Vibeke Strand (410780)
Laure Gossec (4058521)
Clare Proudfoot (5165081)
Chieh-I Chen (4415830)
Matthew Reaney (5424773)
Sophie Guillonneau (5424776)
Toshio Kimura (5424779)
Janet van Adelsberg (5424782)
Yong Lin (177139)
Erin Mangan (5424785)
Hubert van Hoogstraten (5079860)
Gerd Burmester (52016)

June 2018

Table S1. LSM changes in RAID individual domain scores from baseline to week 24 with sarilumab 200Â ...

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

Mean DAS parameters and DAS responder rates over time in the total population. (PDF 111 kb

Stanley Cohen (411535)
Rieke Alten (52012)
Hideto Kameda (3399878)
Tomas Hala (5567096)
Sebastiao Radominski (5567099)
Muhammad Rehman (5567102)
Ramesh Palaparthy (4951276)
Karl Schumacher (5567105)
Susanne Schmitt (5567108)
Steven Hua (5567111)
Claudia Ianos (5567114)
K. Sewell (5614937)

July 2018

Supplementary methods and results, supplementary figures and figure legends, and supplementary table...

Additional file 1: of Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

Rieke Alten (52012)
Harald Burkhardt (23413)
Eugen Feist (609857)
Klaus KrĂźger (4763949)
Juergen Rech (4763922)
Andrea Rubbert-Roth (358862)
Reinhard Voll (23411)
Yedid Elbez (4763928)
Christiane Rauch (4763931)

January 2018

is a figure showing mean change from baseline in HAQ-DI scores in response to abatacept administered...

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

ACR20 response rate and mean DAS28â4(ESR) and HAQ-DI over time for patients treated with tofacitin...

Additional file 1: of Health outcomes and unmet needs in patients with long-standing rheumatoid arthritis attending tertiary care in Greece: a cohort study

Dimitrios Boumpas (5800499)
Prodromos Sidiropoulos (424541)
Loukas Settas (6648626)
Piotr Szczypa (578620)
Vassilis Tsekouras (6648629)
Ana Hernandez Daly (6648632)

April 2019

Table S1. Final fitted mixed-effects model across study time points for EQ-5D index score. Table S2....

Vibeke Strand (410780)
Joel Kremer (3475457)
Gene Wallenstein (3475451)
Keith Kanik (3475454)
Carol Connell (3475442)
David Gruben (3475448)
Samuel Zwillich (3475445)
Roy Fleischmann (96247)

November 2015

Numbers needed to treat for ACR 20/50/70 (a), Disease Activity Score based on C reactive protein and...

Vibeke Strand (410780)
Joel Kremer (3475457)
Gene Wallenstein (3475451)
Keith Kanik (3475454)
Carol Connell (3475442)
David Gruben (3475448)
Samuel Zwillich (3475445)
Roy Fleischmann (96247)

November 2015

Rates of reporting normative values for the Health Assessment Questionnaire-Disability Index (HAQ-DI...

Additional file 3: of Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study

Motomu Hashimoto (388292)
Moritoshi Furu (105348)
Wararu Yamamoto (5594390)
Takanori Fujimura (4966762)
Ryota Hara (4966744)
Masaki Katayama (152645)
Akira Ohnishi (4966750)
Kengo Akashi (3486011)
Shuzo Yoshida (525805)
Koji Nagai (4966753)
Yonsu Son (4966759)
Hideki Amuro (4966747)
Toru Hirano (2738686)
Kosuke Ebina (326525)
Ryuji Uozumi (5594393)
Hiromu Ito (164599)
Masao Tanaka (107633)
Koichiro Ohmura (137137)
Takao Fujii (199007)
Tsuneyo Mimori (114039)

August 2018

Table S1. Types of bDMARDs and hazard ratios for bDMARD-free remission failure in bDMARD-naïve patie...

Additional file 7: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Abstract

Extracted data

Additional file 7: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Abstract

Extracted data

Related items

Related items